Victory Capital Management Inc. lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 341,063 shares of the company's stock after buying an additional 27,806 shares during the period. Victory Capital Management Inc. owned about 0.39% of IDEAYA Biosciences worth $8,765,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Covestor Ltd increased its holdings in IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after purchasing an additional 922 shares during the period. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the fourth quarter valued at $35,000. US Bancorp DE increased its holdings in IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after purchasing an additional 689 shares during the period. KBC Group NV increased its holdings in IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company's stock valued at $72,000 after purchasing an additional 513 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in IDEAYA Biosciences in the third quarter valued at $83,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.
IDEAYA Biosciences Trading Down 2.0 %
NASDAQ IDYA traded down $0.38 during trading hours on Friday, hitting $18.58. The company's stock had a trading volume of 879,194 shares, compared to its average volume of 826,330. IDEAYA Biosciences, Inc. has a 52 week low of $16.95 and a 52 week high of $46.40. The company has a market capitalization of $1.63 billion, a PE ratio of -5.63 and a beta of 0.76. The company's 50-day simple moving average is $22.10 and its two-hundred day simple moving average is $27.47.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have weighed in on IDYA shares. Stephens reiterated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Wedbush reiterated an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEAYA Biosciences has an average rating of "Moderate Buy" and a consensus target price of $53.58.
Check Out Our Latest Analysis on IDEAYA Biosciences
About IDEAYA Biosciences
(
Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Featured Stories
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
